FI962584A0 - Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä - Google Patents

Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä

Info

Publication number
FI962584A0
FI962584A0 FI962584A FI962584A FI962584A0 FI 962584 A0 FI962584 A0 FI 962584A0 FI 962584 A FI962584 A FI 962584A FI 962584 A FI962584 A FI 962584A FI 962584 A0 FI962584 A0 FI 962584A0
Authority
FI
Finland
Prior art keywords
growth hormone
compounds
hormone releasing
releasing properties
pct
Prior art date
Application number
FI962584A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI962584A (fi
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thoegersen
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of FI962584A0 publication Critical patent/FI962584A0/fi
Publication of FI962584A publication Critical patent/FI962584A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI962584A 1993-12-23 1996-06-20 Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä FI962584A (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (pt) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14
PCT/DK1994/000485 WO1995017423A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
FI962584A0 true FI962584A0 (fi) 1996-06-20
FI962584A FI962584A (fi) 1996-06-20

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962584A FI962584A (fi) 1993-12-23 1996-06-20 Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä

Country Status (27)

Country Link
US (1) US5767085A (pt)
EP (1) EP0736039B1 (pt)
JP (1) JP3181918B2 (pt)
KR (1) KR100354897B1 (pt)
CN (1) CN1052731C (pt)
AT (1) ATE197158T1 (pt)
AU (1) AU689181B2 (pt)
BR (1) BR9408377A (pt)
CA (1) CA2179597A1 (pt)
CZ (1) CZ293113B6 (pt)
DE (1) DE69426206T2 (pt)
DK (1) DK0736039T3 (pt)
ES (1) ES2153469T3 (pt)
FI (1) FI962584A (pt)
GR (1) GR3035150T3 (pt)
HU (1) HU224345B1 (pt)
IL (1) IL112112A (pt)
MX (1) MX9500072A (pt)
NO (1) NO315561B1 (pt)
NZ (1) NZ277486A (pt)
PL (1) PL181280B1 (pt)
PT (1) PT736039E (pt)
RO (1) RO115635B1 (pt)
SG (1) SG55069A1 (pt)
SK (1) SK281963B6 (pt)
UA (1) UA42747C2 (pt)
WO (1) WO1995017423A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
US5854211A (en) * 1993-12-23 1998-12-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
AU705744B2 (en) 1995-01-27 1999-06-03 Sapphire Therapeutics, Inc. Compounds with growth hormone releasing properties
WO1997000894A1 (en) * 1995-06-22 1997-01-09 Novo Nordisk A/S Compounds with growth hormone releasing properties
ES2268713T3 (es) 1995-12-13 2007-03-16 MERCK & CO., INC. Ensayos de receptores de secretagogos de la hormona de crecimiento.
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0869974B1 (en) * 1995-12-22 2009-03-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
PL329413A1 (en) * 1996-04-24 1999-03-29 Novo Nordisk As Chemical compounds exhibiting properties capable to cause growth hormone release
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0923539B1 (en) * 1996-07-22 2002-06-05 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU3938797A (en) * 1996-08-29 1998-03-19 Novo Nordisk A/S Transdermal delivery of peptides
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
WO1998058950A1 (en) 1997-06-20 1998-12-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
JP4382279B2 (ja) 1998-01-16 2009-12-09 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (en) 1998-08-10 2002-10-31 Merck & Co Inc RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
EP1158996A4 (en) * 1999-02-18 2005-01-12 Kaken Pharma Co Ltd NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
KR20060012008A (ko) * 2003-05-19 2006-02-06 워너-램버트 캄파니 엘엘씨 제어된 입자 크기를 갖는 산화 티타늄을 함유하는 경질젤라틴 캡슐 및 그의 제조방법
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005049792A2 (en) 2003-09-12 2005-06-02 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
WO2005097261A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
PL1789067T3 (pl) * 2004-08-12 2012-10-31 Helsinn Healthcare Sa Zastosowanie związków wpływających stymulująco na wydzielanie hormonu wzrostu do stymulowania motoryki układu żołądkowo-jelitowego
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
BRPI0807046A2 (pt) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
EP2134341B1 (en) * 2007-02-13 2015-06-17 Helsinn Healthcare S.A. Method of treating cell proliferative disorders using growth hormone secretagogues
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
EA201270011A1 (ru) * 2009-06-12 2012-05-30 ХЕЛСИНН ТЕРАПЬЮТИКС (Ю.Эс.), ИНК. Растворы для инфузии и инъекции ипаморелин диацетата
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
US12012467B2 (en) 2017-03-28 2024-06-18 Regents Of The University Of Michigan Small molecule DCN1 inhibitors and therapeutic methods using the same
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
AU549053B2 (en) * 1981-12-28 1986-01-09 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
JPH08502250A (ja) * 1992-09-25 1996-03-12 スミスクライン・ビーチャム・コーポレイション 成長ホルモン放出ペプチド
WO1995014666A1 (en) * 1993-11-24 1995-06-01 Merck & Co., Inc. Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)

Also Published As

Publication number Publication date
CZ183496A3 (en) 1997-02-12
IL112112A0 (en) 1995-03-15
DE69426206D1 (de) 2000-11-30
NO315561B1 (no) 2003-09-22
HU224345B1 (hu) 2005-08-29
PT736039E (pt) 2001-04-30
SK82096A3 (en) 1997-01-08
SK281963B6 (sk) 2001-09-11
JPH09507217A (ja) 1997-07-22
NO962665L (no) 1996-08-23
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
PL181280B1 (pl) 2001-07-31
HU9501947D0 (en) 1995-11-28
IL112112A (en) 2000-06-29
NO962665D0 (no) 1996-06-21
WO1995017423A1 (en) 1995-06-29
AU689181B2 (en) 1998-03-26
EP0736039B1 (en) 2000-10-25
RO115635B1 (ro) 2000-04-28
CN1052731C (zh) 2000-05-24
GR3035150T3 (en) 2001-04-30
UA42747C2 (uk) 2001-11-15
ATE197158T1 (de) 2000-11-15
AU1272495A (en) 1995-07-10
SG55069A1 (en) 1998-12-21
US5767085A (en) 1998-06-16
EP0736039A1 (en) 1996-10-09
ES2153469T3 (es) 2001-03-01
MX9500072A (es) 1997-05-31
NZ277486A (en) 1997-03-24
CN1138335A (zh) 1996-12-18
PL315113A1 (en) 1996-10-14
FI962584A (fi) 1996-06-20
KR100354897B1 (ko) 2003-01-06
JP3181918B2 (ja) 2001-07-03
HUT73497A (en) 1996-08-28
CZ293113B6 (cs) 2004-02-18
BR9408377A (pt) 1997-08-19
CA2179597A1 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
FI962584A0 (fi) Kasvuhormonia vapauttavia ominaisuuksia sisältäviä yhdisteitä
ES2123149T3 (es) Derivados de perhidroisoindol como antagonistas de la substancia p.
NO954320D0 (no) Lyosfærer omfattende gonadotropin
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ITMI931780A1 (it) Tropil 7-azaindolil-3-carbossiamidi
DK0804223T3 (da) Farmaceutiske præparater indeholdende hGH
BR9708854A (pt) Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e para aumentar a taxa e grau de crescimento de animais e uso de um composto
BR9906975A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
AU6722498A (en) Disubstituted biphenyloxazolines
ES2140683T3 (es) Procedimiento para preparar compuestos de benzopirano.
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.
NO960048L (no) Difluorstaton-analoger
NO950114L (no) Amylin-antagonister og agonister

Legal Events

Date Code Title Description
MA Patent expired